
- /
- Supported exchanges
- / F
- / BM8.F
BioMarin Pharmaceutical Inc (BM8 F) stock market data APIs
BioMarin Pharmaceutical Inc Financial Data Overview
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BioMarin Pharmaceutical Inc data using free add-ons & libraries
Get BioMarin Pharmaceutical Inc Fundamental Data
BioMarin Pharmaceutical Inc Fundamental data includes:
- Net Revenue: 3 064 M
- EBITDA: 955 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-07-28
- EPS/Forecast: -0.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioMarin Pharmaceutical Inc News

Societe Generale: shares & voting rights as of 31 August 2025
Société Générale NUMBER OF SHARES COMPOSING CURRENT SHARE CAPITAL AND TOTAL NUMBER OF VOTING RIGHTS AS OF 31 AUGUST 2025 Regulated Information Paris, 9 September 2025 Information about the t...


Volkswagen to invest up to a billion euros in AI by end of decade
MUNICH (Reuters) -Volkswagen will invest up to a billion euros ($1.2 billion) in artificial intelligence by 2030, feeding the technology into every area of its business in a bid to unlock billions in ...

Carcode Mileage Blockers Expands Advanced Odometer Solutions - Spotlight on BMW Curved Display Compatibility and Key Automotive Applications
MILDENHALL, UK / ACCESS Newswire / September 9, 2025 / Carcode Mileage Blockers, a global developer of advanced odometer management technologies, has announced the expansion of its product portfolio w...

Spain Loyalty Programs Intelligence Report 2025 | Market to Reach $2.23 Billion by 2029 - AI and Sustainability Trends Redefine the Competitive Landscape
Company Logo Spain's loyalty market is set to grow 16.1% annually, reaching $1.34 billion by 2025. This report offers a comprehensive analysis of market dynamics, driven by coalition programs like Re...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.